Free Access
Med Sci (Paris)
Volume 22, Number 8-9, Août–Septembre 2006
Page(s) 755 - 760
Section M/S revues
Published online 15 August 2006
  1. Boshoff C, Weiss R. AIDS-related malignancies. Nat Rev Cancer 2002; 2 : 373–82. [Google Scholar]
  2. Gatti RA, Good RA. Occurrence of malignancy in immunodeficiency diseases. A literature review. Cancer 1971; 28 : 89–98. [Google Scholar]
  3. Penn I, Starzl TE. Malignant lymphomas in transplantation patients : a review of the world experience. Int Z Klin Pharmakol Ther Toxikol 1970; 3 : 49–54. [Google Scholar]
  4. Lejeune FJ. High dose recombinant tumour necrosis factor (rTNF alpha) administered by isolation perfusion for advanced tumours of the limbs : a model for biochemotherapy of cancer. Eur J Cancer1995; 31A : 1009–16. [Google Scholar]
  5. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy : moving beyond current vaccines. Nat Med 2004; 10 : 909–15. [Google Scholar]
  6. Pardoll D. Does the immune system see tumors as foreign or self ? Annu Rev Immunol 2003; 21 : 807–39. [Google Scholar]
  7. Van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254 : 1643–7. [Google Scholar]
  8. Boon T, Coulie PG, Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today 1997; 18 : 267–8. [Google Scholar]
  9. Echchakir H, Mami-Chouaib F, Vergnon I, et al. A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. Cancer Res 2001; 61 : 4078–83. [Google Scholar]
  10. Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 2001; 19 : 47–64. [Google Scholar]
  11. Spiotto MT, Yu P, Rowley DA, et al. Increasing tumor antigen expression overcomes « ignorance » to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 2002; 17 : 737–47. [Google Scholar]
  12. Huang AY, Golumbek P, Ahmadzadeh M, et al. Bone marrow-derived cells present MHC class I-restricted tumour antigens in priming of antitumour immune responses. Ciba Found Symp 1994; 187 : 229–44. [Google Scholar]
  13. Huang AY, Bruce AT, Pardoll DM, et al. In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter. Immunity 1996; 4 : 349–55. [Google Scholar]
  14. Gong J, Apostolopoulos V, Chen D, et al. Selection and characterization of MUC1-specific CD8+ T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells. Immunology 2000; 101 : 316–24. [Google Scholar]
  15. Restifo NP, Ying H, Hwang L, et al. The promise of nucleic acid vaccines. Gene Ther 2000;7 : 89–92. [Google Scholar]
  16. Marshall JL, Hoyer RJ, Toomey MA, et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000; 18 : 3964–73. [Google Scholar]
  17. Rosenberg SA, Zhai Y, Yang JC, et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 1998; 90 : 1894–900. [Google Scholar]
  18. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298 : 850–4. [Google Scholar]
  19. Russell JH, White CL, Loh DY, et al. Receptor-stimulated death pathway is opened by antigen in mature T cells. Proc Natl Acad Sci USA 1991; 88 : 2151–5. [Google Scholar]
  20. Rosenberg SA. Shedding light on immunotherapy for cancer. N Engl J Med 2004; 350 : 1461–3. [Google Scholar]
  21. Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353 : 2654–66. [Google Scholar]
  22. Abouzahr S, Bismuth G, Gaudin, C, et al. Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure. Proc Natl Acad Sci USA 2006; 103 : 1428–33. [Google Scholar]
  23. Chouaib S. Integrating the quality of the cytotoxic response and tumor susceptibility into the design of protective vaccines in tumor immunotherapy. J Clin Invest 2003; 111 : 595–7. [Google Scholar]
  24. Dong J, Grunstein J, Tejada M, et al. VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J 2004; 23 : 2800–10. [Google Scholar]
  25. Polverini PJ, Leibovich SJ. Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages. Lab Invest 1984; 51 : 635–42. [Google Scholar]
  26. Silzle T, Randolph GJ, Kreutz M, et al. The fibroblast : sentinel cell and local immune modulator in tumor tissue. Int J Cancer 2004; 108 : 173–80. [Google Scholar]
  27. Perdrizet GA, Kaneko H, Buckley TM, et al. Heat shock protects pig kidneys against warm ischemic injury. Transplant Proc 1990; 22 : 460–1. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.